Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Latest real-world evidence presented at WCO-IOF-ESCEO assesses how Evenity (romosozumab) can help to close the treatment gap in osteoporosis – UCB

Written by | 16 Apr 2024

UCB, announced key findings from the first retrospective patient cohort study in Denmark to observe the characteristics of patients selected for romosozumab treatment in routine clinical practice. The… read more.

Study provides genetic evidence on new osteoporosis drug heart attack risk

Written by | 6 May 2023

New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS. The University of Bristol-led study, published in Arthritis & Rheumatology, analysed… read more.

First new treatment for osteoporosis for over a decade

Written by | 9 Apr 2022

Thousands of people in England and Wales with severe osteoporosis who are at high risk of fracture are set to benefit from a new treatment – romosozumab (Evenity™,… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.